Business
Contract wins and first cash licensing receipts
Aptamer Group plc announced significant commercial progress with £190,000 in new fee-for-service contracts and extensions, including repeat business from top-tier pharmaceutical partners, bringing the FY26 order book to over £2.1 million. Additionally, the company received its first cash licensing receipts of £80,000 from a hot-start PCR Optimer® licence, with an upfront payment of £75,000 expected to contribute passive income equivalent to approximately 15% of annual overhead over three years. These developments, alongside existing cash resources, provide funding runway through to June 2027 and bolster confidence in continued year-on-year revenue growth and progress towards cash-flow break-even. Disclaimer*
About this update from Aptamer Group Plc
[{"type":"text","content":"\n\n \n29 January 2026\n \nAptamer Group plc\n (\"Aptamer\", the \"Company\" or the \"Group\")\n \nFurther repeat contract wins and first cash licensing receipts\n£190,000 of new fee-for-service contracts and extensions, including repeat business with top-tier pharmaceutical partners\nFY26 fee-for-service order book now exceeds £2.1 million\nFirst cash licensing receipts of £80,000 from a hot‑start PCR Optimer® licence\n \nAptamer Group plc (AIM: APTA), the developer of next-generation synthetic binders for the life sciences industry, is pleased to announce £190,000 of new fee-for-service orders and £80,000 of cash licensing receipts, demonstrating sustained commercial momentum and the commencement of high-margin, recurring revenues from its Optimer® platform.\n \nRepeat business from top-tier pharma partners\nNew Optimer® development agreements totalling £155,000 include a further contract with a top‑10 global pharmaceutical company, the second repeat programme with this partner in FY26 alone.\n \nContract extensions worth £35,000 have also been signed with this top‑10 partner and an additional top‑20 pharmaceutical company. These new and extended contracts mean Aptamer now has multiple, ongoing Optimer® programmes with leading industry players, demonstrating sustained adoption of the platform and a growing, diversified fee-for-service revenue base. The Optimers generated under these agreements will support a range of research applications for the Group's pharmaceutical partners, further embedding Optimer® binders within customers' development pipelines.\n \nOptimer® development for novel fertility solutions\nThe Group has secured a second Optimer® discovery and development programme with a leading European medical research centre to generate a specialist anti-blood-clotting (anti-coagulant) Optimer® with a corresponding rapid reversal agent (antidote) for application in novel fertility solutions. Aptamer retains full intellectual property rights for the developed binders, creating potential for high-value downstream licensing and royalty revenues and broader commercial applications beyond the initial programme scope.\n \nFirst cash licensing receipts from hot‑start PCR Optimer®\nAptamer has received its first cash licensing receipts totalling £80,000 from a non-exclusive hot‑start PCR Op...